Launch of generic Lialda expands Mylan’s gastroenterology product offering
PITTSBURGH — Mylan N.V. announced the U.S. launch of mesalamine delayed-release tablets USP, 1.2 g, a generic version of Shire’s Lialda Delayed-Release Tablets. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the induction of remission in patients with active,
